Joon Oh Park

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim, Răzvan Cristescu, Adam J. Bass et al. · Nature Medicine · 2018 · 1.7K citations

Medicine, Cancer Biology, Oncology +17

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 1K citations · Full text

Medicine, Oncology, Pharmacology +8

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9